Shanghai Haohai Biological Technology Co., Ltd. Stock

Equities

6826

CNE100001W69

Medical Equipment, Supplies & Distribution

Market Closed - Hong Kong S.E. 04:08:35 2024-04-19 am EDT 5-day change 1st Jan Change
37.4 HKD -3.86% Intraday chart for Shanghai Haohai Biological Technology Co., Ltd. -5.56% -7.20%

Financials

Sales 2024 * 3.09B 427M 3.35B Sales 2025 * 3.52B 486M 3.81B Capitalization 14.08B 1.94B 15.23B
Net income 2024 * 501M 69.2M 542M Net income 2025 * 599M 82.74M 648M EV / Sales 2024 * 4.55 x
Net cash position 2024 * - 0 0 Net cash position 2025 * - 0 0 EV / Sales 2025 * 3.83 x
P/E ratio 2024 *
-
P/E ratio 2025 *
10.3 x
Employees 2,158
Yield 2024 *
-
Yield 2025 *
2.98%
Free-Float 37.95%
More Fundamentals * Assessed data
Dynamic Chart
Shanghai Haohai's 2023 Profit Rises on Higher Revenue; Shares Rise 5% MT
Shanghai Haohai Biological Technology Co., Ltd. Proposes Final Dividend for the Year Ended 31 December 2023 CI
Shanghai Haohai Biological Technology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Shanghai Haohai Biological Forecasts Up to 138% Boost in 2023 Profit MT
Shanghai Haohai Biological Technology Co., Ltd. Provides Preliminary Unaudited Consolidated Group Earnings Guidance for the Year Ended 31 December 2023 CI
Tranche Update on Shanghai Haohai Biological Technology Co., Ltd.'s Equity Buyback Plan announced on September 27, 2023. CI
Shanghai Haohai Biological Technology Co., Ltd. Announces Resignation of Guo Yongqing as Independent Non-Executive Director, Chairman of Audit Committee, Member of Remuneration and Appraisal Committee and Member of Nomination Committee CI
Haohai Biological Technology's Q3 Profit Rises 34%; Hong Kong Shares Jump 5% MT
Shanghai Haohai Biological Technology Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Tranche Update on Shanghai Haohai Biological Technology Co., Ltd.'s Equity Buyback Plan announced on September 27, 2023. CI
Shanghai Haohai Biological Technology Co., Ltd. commences an Equity Buyback Plan for 1,538,461 shares, representing 0.9% for CNY 200 million, under the auhtorization approved on September 15, 2023. CI
Shanghai Haohai Biological Technology to See Rise in January-September Profit MT
Shanghai Haohai Biological Technology Co., Ltd. Provides Unaudited Consolidated Financial Guidance for the Nine Months Ended 30 September 2023 CI
Shanghai Haohai Biological Technology's Profit Surges 188.9% in H1; Shares Up 3% MT
Shanghai Haohai Biological Technology Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
More news
1 day-3.86%
1 week-3.61%
Current month-6.50%
1 month-9.88%
3 months+0.54%
6 months-2.60%
Current year-7.20%
More quotes
1 week
36.75
Extreme 36.75
39.35
1 month
36.75
Extreme 36.75
43.00
Current year
30.40
Extreme 30.4
43.40
1 year
30.30
Extreme 30.3
50.20
3 years
20.40
Extreme 20.4
150.00
5 years
20.40
Extreme 20.4
150.00
10 years
20.40
Extreme 20.4
150.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 60 07-06-30
Director of Finance/CFO 49 16-07-31
Chief Tech/Sci/R&D Officer 45 09-09-30
Members of the board TitleAgeSince
Director/Board Member 42 07-01-23
Chairman 63 07-01-23
Chief Executive Officer 60 07-06-30
More insiders
Date Price Change Volume
24-04-19 37.4 -3.86% 192 400
24-04-18 38.9 +1.97% 99,900
24-04-17 38.15 +1.19% 288,300
24-04-16 37.7 -1.57% 192,800
24-04-15 38.3 -1.29% 140,000

Delayed Quote Hong Kong S.E., April 19, 2024 at 04:08 am EDT

More quotes
Shanghai Haohai Biological Technology Co., Ltd. is a China-based company principally engaged in biological technology-related businesses. The businesses of the Company include the manufacture and sales of biological and medical hyaluronate, the research and development of biological engineering and pharmaceutical products and the provision of related services. Its products include orthopedics products, medical aesthetics and wound care products, ophthalmology products and anti-adhesion and hemostasis products, among others. Orthopedics products include sodium hyaluronate injection, medical chitosan and medical sodium hyaluronate gel. Medical aesthetics and wound care products include recombinant human epidermal growth factor (rhEGF), among others. Ophthalmology products include ophthalmic viscoelastic devices and lubricant eye drops. Anti-adhesion and hemostasis products include medical collagen sponges, among others. The Company mainly operates businesses in Mainland China.
More about the company
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
35.96 CNY
Average target price
65.08 CNY
Spread / Average Target
+80.99%
Consensus

Annual profits - Rate of surprise